Feasibility and Safety of <scp>Cytosorb</scp> Application in Patients With Acute Liver Failure
Cytosorb appeared to be a feasible and well-tolerated blood purification tool with potential beneficial effects in ALF patients. Improved survival with Cytosorb likely reflects confounding by patient selection and higher HU-LTx rates. Prospective studies are warranted to clarify the clinical impact of adjunctive Cytosorb therapy in ALF patients.
Authors
- Schmid Monika
- Trauner Michael
- Christian Zanchin (ORCID: https://orcid.org/0000-0001-9997-841X)
- Roberto Riva (ORCID: https://orcid.org/0000-0001-5801-1376)
- Sabine Friedrich (ORCID: https://orcid.org/0000-0002-2272-6318)
- Haselwanter Patrick
- Mathias Schneeweiss‐Gleixner (ORCID: https://orcid.org/0009-0001-5296-1212)
- Thomas Reiberger (ORCID: https://orcid.org/0000-0002-4590-3583)
- Lorenz Balcar (ORCID: https://orcid.org/0000-0002-6708-3061)
- Riedl‐Wewalka Marlene
- Fairfield Seanna
Institutions
- Christian Doppler Laboratory for Thermoelectricity (AT)
- Medical University of Vienna (AT)
Publication Details
- Journal
- Liver International
- Published
- 2025-11-14
- DOI
- https://doi.org/10.1111/liv.70420
- Citations
- 1
- Primary Topic
- Liver Disease and Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 1.32